Biogen (BIIB) Intangibles (2009 - 2026)
Biogen (BIIB) recorded quarterly Intangibles of $9.1 billion in Q1 2026, down 1.36% quarter-over-quarter from $9.2 billion in Q4 2025, and down 5.54% on a YoY basis from $9.6 billion in Q1 2025.
Biogen (BIIB) Intangibles (2009 - 2026) Analysis & Trends
Biogen's Intangibles history runs 18 years deep, the most recent figure standing at $9.1 billion for Q1 2026.
- In Q1 2026, Intangibles fell 5.54% year-over-year to $9.1 billion; the TTM figure through Mar 2026 stood at $9.1 billion (down 5.54% YoY), while the FY2025 annual figure was $9.2 billion, down 5.29% from the prior year.
- Intangibles was $9.1 billion for Q1 2026 at Biogen, down from $9.2 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $9.8 billion in Q3 2024 to a low of $100.0 million in Q3 2023.
- Historically, Intangibles has averaged $6.0 billion across 5 years, with a median of $8.3 billion in 2024.
- The sharpest annual moves came in 2023 and 2024: Intangibles tumbled 95.02% in 2023, then surged 9705.5% in 2024.
- A 5-year view of Intangibles shows it stood at $1.9 billion in 2022, then surged by 352.03% to $8.4 billion in 2023, then rose by 15.88% to $9.7 billion in 2024, then fell by 5.29% to $9.2 billion in 2025, then slipped by 1.36% to $9.1 billion in 2026.
- The last three Intangibles figures came in at $9.1 billion (Q1 2026), $9.2 billion (Q4 2025), and $9.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 24.45 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | 9.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.05 Bn |
| Dec 31, 2025 | 9.18 Bn |
| Sep 30, 2025 | 9.33 Bn |
| Jun 30, 2025 | 9.47 Bn |
| Mar 31, 2025 | 9.58 Bn |
| Dec 31, 2024 | 9.69 Bn |
| Sep 30, 2024 | 9.81 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Mar 31, 2024 | 8.28 Bn |
| Dec 31, 2023 | 8.36 Bn |
| Sep 30, 2023 | 100.00 Mn |
| Jun 30, 2023 | 1.78 Bn |
| Mar 31, 2023 | 1.81 Bn |
| Dec 31, 2022 | 1.85 Bn |
| Sep 30, 2022 | 2.01 Bn |
| Jun 30, 2022 | 2.08 Bn |
| Mar 31, 2022 | 2.15 Bn |
| Dec 31, 2021 | 2.22 Bn |
| Sep 30, 2021 | 2.29 Bn |
| Jun 30, 2021 | 2.39 Bn |